Top

Published in:

01-11-2020 | Breast Cancer | Epidemiology

Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type

Authors: Jiyoung Kim, Jee Ye Kim, Han-Byoel Lee, Young Joo Lee, Min-Ki Seong, Namsun Paik, Woo-Chan Park, Sungmin Park, Seung Pil Jung, Soo Youn Bae, Korean Breast Cancer Society

Published in: Breast Cancer Research and Treatment | Issue 2/2020

Abstract

Background

Breast cancer is a heterogeneous disease with various histopathologic subtypes. Except for invasive carcinoma of no special type (NST), other subtypes are rare with limited data. The purpose of this study was to analyze the characteristics and prognosis of special histopathologic subtypes of breast cancer compared to NST.

Methods

A total of 136,140 patients were analyzed using the Korean Breast Cancer Society Registry database between January 1996 and March 2019. The clinicopathologic features and survival outcomes of special type breast carcinoma were compared with those of NST.

Results

The prevalence of special subtypes other than NST was 13.7% (n = 18,633). Compared to NST, patients with lobular, medullary, metaplastic, and micropapillary carcinoma had larger tumors (p < 0.001). Patients with mucinous, tubular, medullary, metaplastic, and cribriform carcinoma presented with less node metastasis (p < 0.001), contrary to patients with micropapillary carcinoma. Patients with lobular, mucinous, tubular, papillary, and cribriform carcinoma presented as luminal A subtype much more often (p < 0.001). Micropapillary carcinoma included more luminal B subtype (p < 0.001). Typically, medullary and metaplastic carcinoma included more triple-negative subtypes (p < 0.001). In survival analysis, only medullary (Hazard Ratio (HzR) 0.542, 95% CI 0.345 to 0.852, p = 0.008) and metaplastic carcinoma (HzR 1.655, 95% CI 1.317 to 2.080, p < 0.001) showed significantly different overall survival from NST by multivariate analysis.

Conclusion

Breast cancer had distinct clinicopathologic features according to histopathologic subtype. However, special types of breast cancer had similar survival outcomes compared to NST when adjusting for other prognostic factors, except for metaplastic carcinoma and medullary carcinoma.

Weigelt B, Geyer FC, Reis-Filho JS (2010) Histological types of breast cancer: how special are they? Mol Oncol 4(3):192–208. https://doi.org/10.1016/j.molonc.2010.04.004CrossRef

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121(1):8–16. https://doi.org/10.1002/cncr.28914CrossRef

Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (2012) WHO Classification of tumours of the breast, 4th edn. The International Agency for Research on Cancer (IARC), Lyon

Gannon LM, Cotter MB, Quinn CM (2013) The classification of invasive carcinoma of the breast. Expert Rev Anticancer Ther 13(8):941–954. https://doi.org/10.1586/14737140.2013.820577CrossRef

Sinn HP, Kreipe H (2013) A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care (Basel) 8(2):149–154. https://doi.org/10.1159/000350774CrossRef

Cserni G (2020) Histological type and typing of breast carcinomas and the WHO classification changes over time. Pathologica 112(1):25–41. https://doi.org/10.32074/1591-951X-1-20CrossRef

Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, Teh BS (2014) Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast. Br J Cancer 111(3):619–622. https://doi.org/10.1038/bjc.2014.301CrossRef

Shi WB, Yang LJ, Hu X, Zhou J, Zhang Q, Shao ZM (2014) Clinico-pathological features and prognosis of invasive micropapillary carcinoma compared to invasive ductal carcinoma: a population-based study from China. PLoS ONE 9(6):e101390. https://doi.org/10.1371/journal.pone.0101390CrossRef

Park I, Kim J, Kim M, Bae SY, Lee SK, Kil WH, Lee JE, Nam SJ (2013) Comparison of the characteristics of medullary breast carcinoma and invasive ductal carcinoma. J Breast Cancer 16(4):417–425. https://doi.org/10.4048/jbc.2013.16.4.417CrossRef

10.

Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Ohlschlegel C, Price KN, Gelber RD, Regan MM, Thurlimann B (2012) Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 23(11):2843–2851. https://doi.org/10.1093/annonc/mds105CrossRef

11.

Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Kim S, Choe JH, Lee JE, Kim JH, Kim JS, Nam SJ, Yang JH (2011) The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat 126(2):471–478. https://doi.org/10.1007/s10549-011-1359-8CrossRef

12.

Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z (2013) Apocrine carcinoma of the breast: a comprehensive review. Histol Histopathol 28(11):1393–1409. https://doi.org/10.14670/HH-28.1393CrossRef

13.

Zhao S, Ma D, Xiao Y, Jiang YZ, Shao ZM (2018) Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. Eur J Surg Oncol 44(4):420–428. https://doi.org/10.1016/j.ejso.2017.11.027CrossRef

14.

Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer S (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea—a report from the Korean Breast Cancer Society. J Clin Oncol 25(17):2360–2368. https://doi.org/10.1200/JCO.2006.10.3754CrossRef

15.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. https://doi.org/10.1200/JCO.2009.25.6529CrossRef

16.

Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11(2):155–168

17.

Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, White VA, Lokuhetty D, Cree IA, Board WHOCoTE (2020) The 2019 WHO classification of tumours of the breast. Histopathology. https://doi.org/10.1111/his.14091CrossRef

18.

Lee JH, Park S, Park HS, Park BW (2010) Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol 8:34. https://doi.org/10.1186/1477-7819-8-34CrossRef

19.

Ko SS, Korean Breast Cancer S (2008) Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996–2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol 98(5):318–323. https://doi.org/10.1002/jso.21110CrossRef

20.

Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW, Youn HJ, Korean Breast Cancer S (2018) Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry. J Breast Cancer 21(1):1–10. https://doi.org/10.4048/jbc.2018.21.1.1CrossRef

21.

Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–156. https://doi.org/10.1186/bcr767CrossRef

22.

Wasif N, Maggard MA, Ko CY, Giuliano AE (2010) Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 17(7):1862–1869. https://doi.org/10.1245/s10434-010-0953-zCrossRef

23.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A, International Breast Cancer Study Group (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014. https://doi.org/10.1200/JCO.2007.14.9336CrossRef

24.

Cao AY, Huang L, Wu J, Lu JS, Liu GY, Shen ZZ, Shao ZM, Di GH (2012) Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population. World J Surg Oncol 10:152. https://doi.org/10.1186/1477-7819-10-152CrossRef

25.

Truin W, Vugts G, Roumen RM, Maaskant-Braat AJ, Nieuwenhuijzen GA, van der Heiden-van der Loo M, Tjan-Heijnen VC, Voogd AC (2016) Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol 23(1):51–57. https://doi.org/10.1245/s10434-015-4603-3CrossRef

26.

Fisher ER, Anderson S, Redmond C, Fisher B (1993) Pathologic findings from the national surgical adjuvant breast project protocol B-06. 10-year pathologic and clinical prognostic discriminants. Cancer 71(8):2507–2514. https://doi.org/10.1002/1097-0142(19930415)71:8<2507:aid-cncr2820710813>3.0.co;2-0CrossRef

27.

Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, Intra M, Montagna E, Cancello G, Cardillo A, Mazza M, Perri G, Iorfida M, Pruneri G, Goldhirsch A, Viale G (2012) Outcome of special types of luminal breast cancer. Ann Oncol 23(6):1428–1436. https://doi.org/10.1093/annonc/mdr461CrossRef

28.

National Comprehensive Cancer Network (2019) Breast Cancer (Version 2. 2019). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 18 July 2019

29.

Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM (2015) Clinicopathological characteristics and survival outcomes of invasive cribriform carcinoma of breast: a SEER population-based study. Medicine (Baltimore) 94(31):e1309. https://doi.org/10.1097/MD.0000000000001309CrossRef

30.

Zheng YZ, Hu X, Shao ZM (2016) Clinicopathological characteristics and survival outcomes in invasive papillary carcinoma of the breast: a SEER population-based study. Sci Rep 6:24037. https://doi.org/10.1038/srep24037CrossRef

31.

Ong CT, Campbell BM, Thomas SM, Greenup RA, Plichta JK, Rosenberger LH, Force J, Hall A, Hyslop T, Hwang ES, Fayanju OM (2018) Metaplastic breast cancer treatment and outcomes in 2500 Patients: a retrospective analysis of a national oncology database. Ann Surg Oncol 25(8):2249–2260. https://doi.org/10.1245/s10434-018-6533-3CrossRef

32.

Nelson RA, Guye ML, Luu T, Lai LL (2015) Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol 22(1):24–31. https://doi.org/10.1245/s10434-014-3890-4CrossRef

33.

Tzanninis IG, Kotteas EA, Ntanasis-Stathopoulos I, Kontogianni P, Fotopoulos G (2016) Management and outcomes in metaplastic breast cancer. Clin Breast Cancer 16(6):437–443. https://doi.org/10.1016/j.clbc.2016.06.002CrossRef

34.

Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG (2018) The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer 9(2):296–303. https://doi.org/10.7150/jca.22280CrossRef

35.

Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R (2018) Histologic heterogeneity of triple negative breast cancer: a national cancer centre database analysis. Eur J Cancer 98:48–58. https://doi.org/10.1016/j.ejca.2018.04.011CrossRef

36.

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S (2019) Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37(7):559–569. https://doi.org/10.1200/JCO.18.01010CrossRef

37.

Miyai K, Schwartz MR, Divatia MK, Anton RC, Park YW, Ayala AG, Ro JY (2014) Adenoid cystic carcinoma of breast: recent advances. World J Clin Cases 2(12):732–741. https://doi.org/10.12998/wjcc.v2.i12.732CrossRef

38.

Kulkarni N, Pezzi CM, Greif JM, Suzanne Klimberg V, Bailey L, Korourian S, Zuraek M (2013) Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base. Ann Surg Oncol 20(7):2236–2241. https://doi.org/10.1245/s10434-013-2911-zCrossRef

39.

Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ (2006) Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 30(8):1002–1007CrossRef

40.

Guo S, Wang Y, Rohr J, Fan C, Li Q, Li X, Wang Z (2016) Solid papillary carcinoma of the breast: a special entity needs to be distinguished from conventional invasive carcinoma avoiding over-treatment. Breast 26:67–72. https://doi.org/10.1016/j.breast.2015.12.015CrossRef

41.

Stamatakos M, Stefanaki C, Stasinou T, Papantoni E, Alexiou I, Kontzoglou K (2011) Intracystic papillary carcinoma of the breast in males. In search of the optimal treatment for this rare disease. Breast Care (Basel) 6(5):399–403. https://doi.org/10.1159/000331386CrossRef

42.

Horowitz DP, Sharma CS, Connolly E, Gidea-Addeo D, Deutsch I (2012) Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast 21(3):350–353. https://doi.org/10.1016/j.breast.2012.02.013CrossRef

43.

Pareja F, Geyer FC, Marchio C, Burke KA, Weigelt B, Reis-Filho JS (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2:16036. https://doi.org/10.1038/npjbcancer.2016.36CrossRef

44.

McDivitt RW, Stewart FW (1966) Breast carcinoma in children. JAMA 195(5):388–390CrossRef

45.

Hull MT, Seo IS, Battersby JS, Csicsko JF (1980) Signet-ring cell carcinoma of the breast: a clinicopathologic study of 24 cases. Am J Clin Pathol 73(1):31–35. https://doi.org/10.1093/ajcp/73.1.31CrossRef

46.

Bartosch C, Mendes N, Rios E, Rodrigues M, Eloy C, Reis CA, Amendoeira I (2015) Morphological features and mucin expression profile of breast carcinomas with signet-ring cell differentiation. Pathol Res Pract 211(8):588–595. https://doi.org/10.1016/j.prp.2015.05.003CrossRef

Title: Characteristics and prognosis of 17 special histologic subtypes of invasive breast cancers according to World Health Organization classification: comparative analysis to invasive carcinoma of no special type
Authors: Jiyoung Kim
Jee Ye Kim
Han-Byoel Lee
Young Joo Lee
Min-Ki Seong
Namsun Paik
Woo-Chan Park
Sungmin Park
Seung Pil Jung
Soo Youn Bae
Korean Breast Cancer Society
Publication date: 01-11-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 2/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05861-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

BTB domain-containing 7 predicts low recurrence and suppresses tumor progression by deactivating Notch1 signaling in breast cancer

Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

Association of RAD51C germline mutations with breast cancer among Bahamians

Breast cancer survival among Japanese individuals and US residents of Japanese and other origins: a comparative registry-based study

Analyzing non-sentinel axillary metastases in patients with T3–T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy

Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway

Keynote webinar | Spotlight on antibody–drug conjugates in cancer